Model Pack Overview – Protein Degrader Model Pack Page
Model Pack Overview – Protein Degrader Model Pack Download PDF “Assess™ enables me to quickly explore design hypotheses, and better understand tradeoffs between PK, Target Engagement, and TMDD of our...Model Pack Overview – Avidity Model Pack Page
Model Pack Overview – Avidity Model Pack Download PDF “Assess™ enables me to quickly explore design hypotheses, and better understand tradeoffs between PK, Target Engagement, and TMDD of our bispecific...Model Pack Overview – Gene Therapy Model Pack Page
Model Pack Overview – Gene Therapy Model Pack Download PDF “Assess™ enables me to quickly explore design hypotheses, and better understand tradeoffs between PK, Target Engagement, and TMDD of our...
Model Pack Overview – Biotherapeutic Model Pack Page
Model Pack Overview - Biotherapeutic Model Pack Download PDF “Assess™ enables me to quickly explore design hypotheses, and better understand tradeoffs between PK, Target Engagement, and TMDD of our bispecific...Model Pack Overview – Cell Engager Model Pack Page
Model Pack Overview - Cell Engager Model Pack Download PDF “Assess™ enables me to quickly explore design hypotheses, and better understand tradeoffs between PK, Target Engagement, and TMDD of our...
Mastering Value Storytelling with Data-Driven Stories Blog Post
Unlocking the Power of Storytelling in Healthcare Communication In the realm of healthcare communication, persuasion is key. Whether you are engaging with payers, providers, or policymakers, the ability to convey…
Enhancing Pharmacokinetics Workflows at Charles River Blog Post
Solutions Preclinical Products Phoenix™ Integral Data Repository The challenge Charles River, a global leader in drug development, sought to improve its pharmacokinetics (PK) analysis across its seven worldwide sites. 有了人工...ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation Blog Post
Abstract Immune checkpoint inhibitors (ICI) have transformed cancer treatment. However, only a minority of patients achieve a profound response. Many patients are innately resistant while others acquire resistance to ICIs….
